RE: Cowen & Co. Initiates Coverage....OutPerform
Still don't have all the details but they're starting coverage with an OutPerform and an Open Price Target....
https://www.briefing.com/GeneralContent/Investor/Active/ArchiveSearch/ArchiveSearchInvestor.aspx?Date=19-Dec-07&PageName=Upgrades/Downgrades
"---INITIATE STORY ABOUT TTHI FROM COWEN & CO. ----Cowen believes Transition Therapeutics offers a low risk opportunity to benefit from an improvement in visibility on clinical profile and potential of ELND-005/AZD-103."
This company Cowen & Co. has put tremendous resources into analyzing the Alzheimers Market. They are often quoted in news and articles and are considered by many to be one of the best sources of information on most anything related to the Alzheimers market.
GPP All.......